Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,454.00GBp
23 May 2018
Change (% chg)

0.00 (+0.00%)
Prev Close
5,454.00
Open
5,451.00
Day's High
5,502.00
Day's Low
5,418.00
Volume
2,144,367
Avg. Vol
2,087,970
52-wk High
5,585.07
52-wk Low
4,260.00

Select another date:

Fri, May 25 2018

Photo

AstraZeneca cancer drug hits second goal by extending survival

LONDON AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.

AstraZeneca cancer drug hits second goal by extending survival

LONDON, May 25 AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.

AstraZeneca potassium drug finally approved, threatening Vifor

LONDON The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.

AstraZeneca potassium drug finally approved, threatening Vifor

LONDON, May 21 The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.

AstraZeneca pay report rejected by 35 percent of shareholders

LONDON More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme.

AstraZeneca pay report rejected by 35 pct of shareholders

LONDON, May 18 More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme.

UPDATE 2-AstraZeneca insists future is bright after big Crestor sales hit

* Q1 sales and earnings miss forecasts as Crestor, costs weigh

BRIEF-AstraZeneca CEO Says More Drug Industry Consolidation Possible

May 18 AstraZeneca PLC CEO Pascal Soriot tells reporters:

AstraZeneca hit by falling Crestor sales, higher costs

LONDON, May 18 Generic competition to cholesterol fighter Crestor and higher costs hit AstraZeneca in the first quarter, despite good sales of new drugs, but the group said on Friday it remained on track for a promised return to sales growth in 2018.

AstraZeneca's drug Fasenra flops in COPD trial

LONDON AstraZeneca's said its first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Select another date: